[Skip to Content]

Upstate Active Clinical Trials

Study Title:

TRITON3:A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus
Physician's Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer
Associated with Homologous Recombination Deficiency

What is the purpose of the study?

The purpose of this study is to compare the safety and efficacy of rucaparib with that of comparator treatments in patients with prostate cancer, and who have mutations in BRCA or ATM.

Upstate Institutional Review Board (IRB) Number:

1040351

Study/Protocol ID:

CO-338-063

Study Phase:

Phase III

Patient Age Group:

Adults

Principal Investigator:

Bernard J Poiesz, MD

What is involved if I participate?

  • How long is the study?
    The study is expected to last 4 years with individual participants expected to be treated and followed for about a year. The study has optional consent for continuing treatment with rucaparib following disease progression.
  • Is transportation provided or reimbursed?
    Yes
  • Is parking provided or reimbursed?
    Yes
  • What tests and procedures are involved?
    Biomarker testing of blood and tumor tissue, physical exams, blood tests, ECGs, CT and bone scans, questionnaires

Where will the study take place?

This study will take place at the Cancer Center. The satellite sites will only be used for consenting. All other study procedures are to be performed at the Cancer Center.

ClinicalTrials.Gov ID:

NCT02975934

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Patricia M Benz
Phone: 315-464-8253
Email: benzp@upstate.edu

Return to Previous Page || Search Again

Top